Table 1.
Baseline disease and demographic characteristics (Maximal Usage Pharmacokinetic and Safety Study [Study 107; NCT04279119]; safety population)
| Variable | Adolescents [n = 6] | Adults [n = 20] |
|---|---|---|
| Age, years | ||
| Mean (SD) | 14.7 (1.03) | 52.6 (12.63) |
| Median | 15.0 | 54.0 |
| Min, max | 13, 16 | 27, 74 |
| Male sex [n (%)] | 4 (66.7) | 14 (70.0) |
| Ethnicity, Hispanic or Latino [n (%)] | 3 (50) | 17 (85.0) |
| Race [n (%)] | ||
| Asian | 1 (16.7) | 0 |
| Black/African American | 0 | 1 (5.0) |
| White | 5 (83.3) | 18 (90.0) |
| BSA, % | ||
| Mean (SD) | 13.0 (3.58) | 27.5 (7.76) |
| Median | 12.0 | 24.5 |
| Min, max | 10.0, 20.0 | 21.0, 45.0 |
| IGA [n (%)] | ||
| Moderate | 6 (100) | 19 (95.0) |
| Severe | 0 | 1 (5.0) |
| mPASI | ||
| Mean (SD) | 11.9 (6.2) | 19.7 (5.7) |
| Median | 12.9 | 19.2 |
| Min, max | 1.7, 18.9 | 7.2, 28.8 |
BSA body surface area, IGA Investigator Global Assessment, mPASI modified Psoriasis Area Severity Index, min minimum, max maximum, SD standard deviation